EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG)

C. Terret; S. Zanetta; H. Roche; J.H.M. Schellens; M.N. Faber; J. Wanders; M. Ravic; J.P. Droz

EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG)

C. Terret, S. Zanetta, H. Roche, J.H.M. Schellens, M.N. Faber, J. Wanders, M. Ravic, J.P. Droz

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1097-1104
Number of pages	8
Journal	European Journal of Cancer
Volume	39
Publication status	Published - 2003

Keywords

Genetics
Farmacie/Biofarmaceutische wetenschappen (FARM)
Farmacie(FARM)
Biochemistry
Biomedische technologie en medicijnen
Analytical chemistry

Cite this

Terret, C., Zanetta, S., Roche, H., Schellens, J. H. M., Faber, M. N., Wanders, J., Ravic, M., & Droz, J. P. (2003). EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG). European Journal of Cancer, 39, 1097-1104.

@article{cbba1626a8754f2d8a43a93426b59809,

title = "EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG)",

keywords = "Genetics, Farmacie/Biofarmaceutische wetenschappen (FARM), Farmacie(FARM), Biochemistry, Biomedische technologie en medicijnen, Analytical chemistry",

author = "C. Terret and S. Zanetta and H. Roche and J.H.M. Schellens and M.N. Faber and J. Wanders and M. Ravic and J.P. Droz",

year = "2003",

language = "Undefined/Unknown",

volume = "39",

pages = "1097--1104",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

Terret, C, Zanetta, S, Roche, H, Schellens, JHM, Faber, MN, Wanders, J, Ravic, M & Droz, JP 2003, 'EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG)', European Journal of Cancer, vol. 39, pp. 1097-1104.

EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG). / Terret, C.; Zanetta, S.; Roche, H. et al.
In: European Journal of Cancer, Vol. 39, 2003, p. 1097-1104.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG)

AU - Terret, C.

AU - Zanetta, S.

AU - Roche, H.

AU - Schellens, J.H.M.

AU - Faber, M.N.

AU - Wanders, J.

AU - Ravic, M.

AU - Droz, J.P.

PY - 2003

Y1 - 2003

KW - Genetics

KW - Farmacie/Biofarmaceutische wetenschappen (FARM)

KW - Farmacie(FARM)

KW - Biochemistry

KW - Biomedische technologie en medicijnen

KW - Analytical chemistry

M3 - Article

SN - 0959-8049

VL - 39

SP - 1097

EP - 1104

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Terret C, Zanetta S, Roche H, Schellens JHM, Faber MN, Wanders J et al. EORTC Early Clinical Study Group. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. A study by the EORTC Early Clinical Study Group (ECSG). European Journal of Cancer. 2003;39:1097-1104.